Last reviewed · How we verify

Ganoderma lucidum

Second Affiliated Hospital, School of Medicine, Zhejiang University · FDA-approved active Small molecule

Ganoderma lucidum (reishi mushroom) modulates immune function and promotes apoptosis through polysaccharide and triterpene constituents that enhance natural killer cell activity and reduce inflammatory cytokines.

Ganoderma lucidum (reishi mushroom) modulates immune function and promotes apoptosis through polysaccharide and triterpene constituents that enhance natural killer cell activity and reduce inflammatory cytokines. Used for Cancer adjuvant therapy and immune support, Fatigue and quality of life in cancer patients.

At a glance

Generic nameGanoderma lucidum
Also known aslingzhi trearment
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Drug classHerbal/botanical immunomodulator
ModalitySmall molecule
Therapeutic areaOncology, Immunology
PhaseFDA-approved

Mechanism of action

The fruiting body and spores of Ganoderma lucidum contain bioactive compounds including beta-glucans and ganoderic acids that act as biological response modifiers. These constituents enhance immune surveillance, promote tumor cell death through multiple pathways, and reduce systemic inflammation. The mechanism is multifactorial rather than targeting a single molecular receptor.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: